Tiers lieu: UXCARE
Led by: GIP Genopole
Key consortium members: Centre Hospitalier Sud-Francilien (CHSF), Société d’Accélération de Transfert Technologique (SATT) Paris-Saclay, European Institute of Innovation and Technology (EIT) Health France, Centre d'Étude et de Recherche sur l'Intensification du Traitement du Diabète (CERITD)
The UXCARE Tiers-lieu focuses on innovative digital solutions designed to improve diabetes care. It facilitates the design of new products, services, and care pathways centered on user needs, and provides companies and healthcare facilities with technologically advanced solutions the opportunity to test them in real-world settings and roll them out under optimal conditions.
Le Tiers lieu offre ses services
UXCARE provides healthcare companies and professionals with an optimal testing environment for evaluating and rolling out new healthcare technologies on a regional scale.
UXCARE is based on an innovative healthcare model that combines:
- A leading university hospital department in diabetology, recognized for its expertise and numerous pilot initiatives in digital health and community care;
- 3 “non-hospital” care facilities and a mobile medical team providing a bridge between the community and the hospital to reach vulnerable and at-risk populations (adolescents, young adults, the elderly, etc.);
- A specialized “diabetic foot” unit providing multidisciplinary follow-up and optimized patient care (a cohort of over 300 patients);
- A multidisciplinary team (dietitian, psychologist, etc.) and medical-social services.
The UXCARE Tiers-Lieu offers a comprehensive support process from design through to market launch:
- 360° audit and strategic mentoring;
- Management and oversight of real-world field trials (access to infrastructure and monitoring data to test the effectiveness and acceptability of digital solutions, medico-economic studies);
- Regulatory and certification consulting;
- Market access strategy and procurement policy;
- Open innovation program.
The Tiers-Lieu Projects
Project: MFDeep
Solution Provider: NeuTigers France
Solution: MFDeep is an innovative digital solution based on artificial intelligence, designed to predict fetal weight in pregnant women with gestational diabetes. By leveraging the continuous collection and analysis of physiological data via a smartwatch, this solution helps anticipate the risks of fetal macrosomia and proactively adapt obstetric care.
Need: Gestational diabetes increases the risk of fetal macrosomia, which can lead to obstetric complications such as preterm births, shoulder dystocia, and avoidable cesarean sections. Currently, fetal weight assessment relies primarily on ultrasounds, which have limited accuracy. MFDeep aims to improve this prediction in a non-invasive, accessible, and real-time manner.
Contribution of the Tiers-lieu: The Tiers-lieu UXCARE supports NeuTigers in the clinical and medico-economic evaluation of MFDeep at the Centre Hospitalier Sud Francilien (CHSF). This trial involves recruiting a cohort of patients to validate the algorithm, compare its accuracy to conventional methods, and prepare for CE marking in anticipation of clinical deployment.
Project: PREDIDIAB
Solution provider: PrediDIAB
Solution: PrediDIAB is a predictive test designed for young adults with a parent who has diabetes. It combines a clinical questionnaire with genetic analysis based on a saliva test to estimate the probability and age of onset of type 2 diabetes, thereby enabling personalized prevention.
Need: Type 2 diabetes is a chronic disease with a rapidly rising incidence, often diagnosed late. Currently, existing predictive tools offer limited discrimination and come too late in patients’ lives. PrediDIAB aims to identify at-risk individuals early so that tailored prevention strategies can be offered.
Contribution of Tiers-lieu: The UXCARE Tiers-Lieu facilitates clinical trials of the PrediDIAB test, particularly through the CHSF and its diabetes care network. The prospective clinical study aims to validate the test’s efficacy compared to existing predictive tools and to collect the data necessary for its CE marking, with a view to integrating it into the diabetes prevention pathway.